XenoPort
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, XenoPort sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
XenoPort: 19 sponsored US clinical trials, none currently recruiting.
XenoPort sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 3 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Restless Legs Syndrome, with 2 trials.
Top-decile sponsor footprint
XenoPort ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
NCT01668667
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
NCT01516372
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
NCT01476124
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
NCT01411124
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
NCT01359566
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
NCT01171313
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT00978016
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
NCT00914602
Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)
NCT00833391
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
NCT00817986
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
NCT00748098
Prevention Study in Adult Patients Suffering From Migraine Headaches
NCT00742209
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
NCT00617461
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
NCT00643760
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
NCT00619476
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
NCT00557973
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
NCT00557401
Simulated Driving Study in Restless Legs Syndrome
NCT01332318
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
NCT01332305
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 11 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
How the XenoPort early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 3 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Restless Legs Syndrome (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
XenoPort: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
XenoPort sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this XenoPort page
19 registered trials is a research-attention snapshot, not an endorsement of XenoPort or any single study.
- None of XenoPort's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Restless Legs Syndrome is the condition XenoPort studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Restless Legs Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
XenoPort pipeline card: 19 registered trials from official public datasets.Report a data error.